Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
Twenty patients with advanced Raynaud's phenomenon, in 14 of whom it was secondary to scleroderma, were treated with stanozolol, an anabolic steroid that enhances natural fibrinolysis. All showed an increase in hand blood flow and a reduction in symptoms during treatment. This response may have been caused by the lysis of fibrin deposited in the digital arteries and the reduction of plasma viscosity. Stanozolol is a useful addition to the treatment of patients with advanced Raynaud's phenomenon who have trophic changes.
D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity; D001831:Body Temperature; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006225:Hand / Q000098:blood supply; D006801:Humans; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000097:blood / Q000188:drug therapy*; D013197:Stanozolol / Q000494:pharmacology / Q000627:therapeutic use*
D013197:Stanozolol